Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Medical Specialties
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MDT | Medtronic PLC | 3.71% | 108.04 | 0.6% | $450.59m | |
| ABT | Abbott Laboratories | -0.44% | 85.18 | 0.8% | $410.28m | |
| TMO | Thermo Fisher Scientific Inc. | -0.76% | 277.40 | 1.0% | $382.62m | |
| ALGN | Align Technology, Inc. | -0.48% | 176.77 | 6.3% | $350.11m | |
| ISRG | Intuitive Surgical, Inc. | -0.13% | 494.87 | 2.4% | $291.78m | |
| BDX | Becton, Dickinson and Company | 0.20% | 251.99 | 1.1% | $274.50m | |
| SYK | Stryker Corporation | 0.00% | 218.64 | 1.3% | $235.96m | |
| EW | Edwards Lifesciences Corporation | 0.57% | 223.77 | 1.2% | $227.26m | |
| BSX | Boston Scientific Corporation | 0.18% | 42.82 | 1.1% | $214.98m | |
| ZBH | Zimmer Biomet Holdings, Inc. | -0.05% | 138.49 | 1.7% | $205.15m | |
| BAX | Baxter International Inc. | -0.20% | 87.70 | 1.7% | $196.33m | |
| ABMD | ABIOMED, Inc. | 1.55% | 195.29 | 3.3% | $161.40m | |
| DXCM | DexCom, Inc. | 1.01% | 165.24 | 8.3% | $154.51m | |
| WAT | Waters Corporation | -0.14% | 209.58 | 3.8% | $119.13m | |
| IDXX | IDEXX Laboratories, Inc. | 0.29% | 280.34 | 3.7% | $112.43m |
Company Profile
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Cardiovascular, Rhythm Management, and MedSurg. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease, and other cardiovascular disorders including structural heart conditions. The Rhythm Management segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal, and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.